This content is only available within our institutional offering.

08 Aug 2024
Hikma Pharmaceuticals (HIK LN, 2,340p, Buy) (Company Update) - 1H24 results: upgraded FY24 guidance implies c.+5% at EBIT

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Hikma Pharmaceuticals (HIK LN, 2,340p, Buy) (Company Update) - 1H24 results: upgraded FY24 guidance implies c.+5% at EBIT
Hikma Pharmaceuticals Plc (HIK:LON) | 1,900 0 0.0% | Mkt Cap: 4,216m
- Published:
08 Aug 2024 -
Author:
Miles Dixon | Leolie Telford-Cooke -
Pages:
8 -